Document Detail

Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.
MedLine Citation:
PMID:  7834999     Owner:  NLM     Status:  MEDLINE    
1. Tumour necrosis factor is a proinflammatory macrophage-derived polypeptide cytokine. Its participation in disease processes has been usually inferred from data obtained from experiments in vitro or from measurements of its plasma circulating levels. To investigate its role in chronic ulcerative colitis, we have quantified in vivo the steady-state release of tumour necrosis factor into the colonic lumen. 2. We studied 19 patients with untreated active ulcerative colitis and seven patients with irritable bowel syndrome as controls. A group of seven patients with active ulcerative colitis were studied before and after 4 weeks on treatment with oral 5-aminosalicylic acid. By means of an intracolonic double-lumen perfusion tube, an isotonic solution was continuously infused 50 cm from the anal verge at a rate of 5 ml/min, and was recovered 30 cm distally by siphonage. Effluents were assayed for tumour necrosis factor by a specific e.l.i.s.a. and for prostaglandin E2 and leukotriene B4 by specific r.i.a.s. 3. The intracolonic release of tumour necrosis factor was undetectable in patients with irritable bowel syndrome, whereas measurable release occurred in 15 out of 19 patients with active ulcerative colitis (P < 0.01). Prostaglandin E2 and leukotriene B4 release were also increased in active ulcerative colitis by comparison with irritable bowel syndrome (P < 0.01). Five out of seven patients with colitis improved with 5-aminosalicylic acid treatment, and tumour necrosis factor release became undetectable or decreased markedly (P < 0.05 compared with before treatment). However, tumour necrosis factor release remained high in the non-responder patients. 4. These findings indicate that intracolonic immunoreactive tumour necrosis factor release is enhanced in active chronic ulcerative colitis, becoming undetectable when mucosal lesions are healed. These results suggest that the luminal release of tumour necrosis factor may serve as an objective index of inflammatory activity in patients with chronic ulcerative colitis.
F Casellas; M Papo; F Guarner; M Antolín; J R Armengol; J R Malagelada
Related Documents :
9870799 - Inflammatory bowel disease in saudi arabia: presentation and initial management.
8240889 - Radiology of the ileal j-pouch-anal anastomosis (ipaa).
1634069 - Familial aggregation of inflammatory bowel disease in northern italy: a multicenter stu...
12790919 - Histological changes associated with the use of intravenous cyclosporin in the treatmen...
6379849 - The o.m.g.e. multinational inflammatory bowel disease survey 1976-1982. a further repor...
22705059 - Rapid improvement of renal function in patients with acute pulmonary embolism indicates...
8517949 - Warm body, cold heart surgery. clinical experience in 2817 patients.
19162229 - Effectiveness and tolerability of rufinamide in children and adults with refractory epi...
22301769 - Detection of interstitial lung disease in systemic sclerosis through partitioning of lu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical science (London, England : 1979)     Volume:  87     ISSN:  0143-5221     ISO Abbreviation:  Clin. Sci.     Publication Date:  1994 Oct 
Date Detail:
Created Date:  1995-02-28     Completed Date:  1995-02-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7905731     Medline TA:  Clin Sci (Lond)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  453-8     Citation Subset:  IM    
Digestive System Research Unit, Hospital General Vall d'Hebron, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aminosalicylic Acids / therapeutic use
Biological Markers
Colitis, Ulcerative / drug therapy,  metabolism*
Colon / metabolism*
Colonic Diseases, Functional / metabolism
Dinoprostone / metabolism
Leukotriene B4 / metabolism
Middle Aged
Tumor Necrosis Factor-alpha / immunology,  metabolism*
Reg. No./Substance:
0/Aminosalicylic Acids; 0/Biological Markers; 0/Tumor Necrosis Factor-alpha; 363-24-6/Dinoprostone; 71160-24-2/Leukotriene B4; 89-57-6/Mesalamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Plasma endogenous digoxin-like substance levels are dependent on blood O2 in man.
Next Document:  Model for whole body production of tumour necrosis factor-alpha in experimental endotoxaemia in heal...